Therapeutic efficacy of a novel non-peptide αvβ3 integrin antagonist for pathological retinal angiogenesis in mice

Experimental Eye Research

Volumn 129, Issue , 2014, Pages 119-126

  Li, Yong Jie ^a   Li, Xiao Hong ^a   Wang, Liang Fen ^a   Kuang, Xi ^a   Hang, Zhi Xiong ^a   Deng, Yong ^a   Du, Jun Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Integrin av 3; Non peptide integrin antagonist; Oxygen induced retinopathy

Indexed keywords

3 [3 (6 GUANIDINO 1 OXOISOINDOLIN 2 YL)PROPANAMIDO] 3 (PYRIDIN 3 YL)PROPANOIC ACID; ALPHAVBETA3 INTEGRIN ANTAGONIST; ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PATHOLOGICAL RETINAL ANGIOGENESIS; PROTEIN PHOSPHORYLATION; RETINA NEOVASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; RETINAL NEOVASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED C57BL; RETINAL NEOVASCULARIZATION;

EID: 84910640763     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.11.004     Document Type: Article

References (44)

1. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1994, 118:445-450.
2. Alghisi G.C., Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006, 13:113-135.
3. Aiello L.P. Angiogenic pathways in diabetic retinopathy. N.Engl. J. Med. 2005, 353:839-841.
4. Belvisi L., Riccioni T., Marcellini M., Vesci L., Chiarucci I., Efrati D., Potenza D., Scolastico C., Manzoni L., Lombardo K., et al. Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist. Mol. Cancer Ther. 2005, 4:1670-1680.
5. Bianchi-Smiraglia A., Paesante S., Bakin A.V. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2013, 32:3049-3058.
6. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
7. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J.Clin. Invest. 1995, 96:1815-1822.
8. Cary L.A., Chang J.F., Guan J.L. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J.Cell Sci. 1996, 109:1787-1794.
9. Connor K.M., Krah N.M., Dennison R.J., Aderman C.M., Chen J., Guerin K.I., Sapieha P., Stahl A., Willett K.L., Smith L.E. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 2009, 4:1565-1573.
10. Dal Monte M., Casini G., la Marca G., Isacchi B., Filippi L., Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp. Eye Res. 2013, 111:27-35.
11. Danen E.H., Aota S., van Kraats A.A., Yamada K.M., Ruiter D.J., van Muijen G.N. Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1. J.Biol. Chem. 1995, 270:21612-21618.
12. Deliyanti D., Miller A.G., Tan G., Binger K.J., Samson A.L., Wilkinson-Berka J.L. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. Hypertension 2012, 3:607-613.
13. Doerr M.E., Jones J.I. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J.Biol. Chem. 1996, 271:2443-2447.
14. Edwards L.A., Woo J., Huxham L.A., Verreault M., Dragowska W.H., Chiu G., Rajput A., Kyle A.H., Kalra J., Yapp D., et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol. Cancer Ther. 2008, 7:59-70.
15. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J.Clin. Invest. 1999, 103:1227-1230.
16. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 2001, 13:555-562.
17. Gentilucci L., Cardillo G., Spampinato S., Tolomelli A., Squassabia F., De Marco R., Bedini A., Baiula M., Belvisi L., Civera M. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics. J.Med. Chem. 2010, 53:106-118.
18. Gilmore A.P., Metcalfe A.D., Romer L.H., Streuli C.H. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J.Cell Biol. 2000, 149:431-446.
19. Hodivala-Dilke K. Alpha v beta 3 integrin and angiogenesis: a moody integrin in a changing environment. Curr. Opin. Cell Biol. 2008, 20:514-519.
20. Hood J.D., Frausto R., Kiosses W.B., Schwartz M.A., Cheresh D.A. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J.Cell Biol. 2003, 162:933-943.
21. Humar R., Kiefer F.N., Berns H., Resink T.J., Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis invitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002, 16:771-780.
22. Iliaki E., Poulaki V., Mitsiades N., Mitsiades C.S., Miller J.W., Gragoudas E.S. Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, 50:4898-4904.
23. Ilic D., Furuta Y., Kanazawa S., Takeda N., Sobue K., Nakatsuji N., Nomura S., Fujimoto J., Okada M., Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377:539-544.
24. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J.Clin. Invest. 1973, 52:2745-2756.
25. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J.Biol. Chem. 1996, 271:17771-17778.
26. Lahdenranta J., Sidman R.L., Pasqualini R., Arap W. Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. FASEB J. 2007, 21:3272-3278.
27. Legler D.F., Wiedle G., Ross F.P., Imhof B.A. Superactivation of integrin alpha v beta 3 by low antagonist concentrations. J.Cell Sci. 2001, 114:1545-1553.
28. Mas-Moruno C., Beck J.G., Doedens L., Frank A.O., Marinelli L., Cosconati S., Novellino E., Kessler H. Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation. Angew. Chem. Int. Ed. Engl. 2011, 50:9496-9500.
29. Naik M.U., Naik U.P. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin αvβ3 specific. J.Cell Sci. 2006, 119:490-499.
30. Philip B., Ito K., Moreno-Sánchez R., Ralph S.J. HIF expression and the role of hypoxic microenvironments within primary tumors as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013, 34:1699-1707.
31. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., Da Violante G., Gourlaouen M., Salih M., Jones M.C., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 2009, 15:392-400.
32. Santulli R.J., Kinney W.A., Ghosh S., Decorte B.L., Liu L., Tuman R.W., Zhou Z., Huebert N., Bursell S.E., Clermont A.C., et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J.Pharmacol. Exp. Ther. 2008, 324:894-901.
33. Schlaepfer D.D., Jones K.C., Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol. Cell Biol. 1998, 18:2571-2585.
34. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90:1243-1250.
35. Somanath P.R., Malinin N.L., Byzova T.V. Cooperation between integrin alpha v beta 3 and VEGFR 2 in angiogenesis. Angiogenesis 2009, 12:177-185.
36. Stahl A., Connor K.M., Sapieha P., Chen J., Dennison R.J., Krah N.M., Seaward M.R., Willett K.L., Aderman C.M., Guerin K.I., Hua J., Löfqvist C., Hellström A., Smith L.E. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51:2813-2826.
37. Stupp R., Ruegg C. Integrin inhibitors reaching the clinic. J.Clin. Oncol. 2007, 25:1637-1638.
38. Takagi H., Suzuma K., Otani A., Oh H., Koyama S., Ohashi H., Watanabe D., Ojima T., Suganami E., Honda Y. Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. Jpn. J. Ophthalmol. 2002, 46:270-278.
39. Tang C.H., Lu D.Y., Tan T.W., Fu W.M., Yang R.S. Ultrasound induces hypoxia-inducible factor-1 activation and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of rapamycin pathway in osteoblasts. J.Biol. Chem. 2007, 282:25406-25415.
40. Terai Y., Abe M., Miyamoto K., Koike M., Yamasaki M., Ueda M., Ueki M., Sato Y. Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the blockade of integrin αvβ3 on vascular endothelial cells. J.Cell Physiol. 2001, 188:394-402.
41. Tsou R., Isik F.F. Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol. Cell Biochem. 2001, 224:81-89.
42. Wilkinson-Berka J.L., Jones D., Taylor G., Jaworski K., Kelly D.J., Ludbrook S.B., Willette R.N., Kumar S., Gilbert R.E. SB-267268, a nonpeptidic antagonist of alpha (v) beta3 and alpha (v) beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2006, 47:1600-1605.
43. Witmer A.N., van Blijswijk B.C., van Noorden C.J., Vrensen G.F., Schlingemann R.O. Invivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J.Histochem. Cytochem. 2004, 52:39-52.
44. Yoshida T., Gong J., Xu Z., Wei Y., Duh E.J. Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp. Eye Res. 2012, 94:41-48.